Navigation Links
Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success

NEW YORK, July 7 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Building Biotech Technology Transfer Opportunities: Sponsor and developer strategies for success

Drug developers have long been under pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition. Current weak economic conditions have exacerbated these challenges with sweeping R&D staff and budget reductions. In order to remain competitive, drug makers must now do more with less. Technology transfer, particularly of new biotechnologies that offer novel means to address unmet medical needs, offer a way to cost effectively address these challenges. They also provide technology developers with a mechanism to monetize their inventions.

However, while some drug makers and technology developers have optimized their biotech tech transfer methodologies and have developed sophisticated processes to select, monitor and manage a wide range of relationships, many other biotech tech transfer projects fail. A large proportion of these failures could be averted as many of the most common reasons for failure are preventable problems relating to due diligence failures, shortcomings in deal structure, management changes, cultural challenges, and inappropriate project organization and expectations. This report provides details on how to avoid these common pitfalls with case studies that illustrate best practices.

Key features of this report

• Discussion of the factors leading to current imperatives to increased biotech tech transfer.

• Detailed descriptions of both effective and ineffective biotech tech transfer approaches.

• In depth analysis of the types of different biotech tech transfer relationships, their advantages and disadvantages.

• More than 10 case studies that illustrate biotech tech transfer best practices.

• Comprehensive discussion of offshore biotech tech transfer, particularly focusing on India and China.

Scope of this report

• Understand the driving forces behind biotech tech transfer.

• Save time and money with the report's succinct compilation and analysis of current biotech tech transfer trends.

• Learn how biotech tech transfer will evolve over the next several years and why.

• Assess your competitive position vis-à-vis other technology sponsors or technology developers and learn about biotech tech transfer best practices via detailed case studies.

• Understand the reasons behind biotech tech transfer success and failure.

• Develop strategies to optimize your biotech tech transfer methodologies and protocols.

Key Market Issues

• The drug development industry is undergoing a significant change which may permanently re-shape product development activities. Many industry experts believe the industry is shrinking; at the very least, the focus is shifting from large in-house research teams to smart approaches, strategic outsourcing and technology transfer.

• Although cost cutting has previously not been a concern for R&D departments, the current economic environment has brought expense reduction programs into research labs. Most of the leading drug makers have recently undertaken and/or are currently in the midst of broad R&D cost cutting programs.

• Biotechnology offers a means to address unmet medical needs, particularly via personalized medicine, which small molecule approaches do not. With more than 3,500 biotech drug companies around the world, many have developed unique technologies and approaches to drug development.

• Because drug makers must continue to introduce new products, maintaining high productivity is key. Biotech tech transfer offers a means to achieve this by providing technology sponsors with access to new technologies.

Key findings from this report

• After a decline in 2008 to 53 deals from 74 deals in 2007, biotech technology transfer volume for human medicines spiked in 2009 to 121 deals. Chapter 1

• More than half of biotech tech transfer deals fail. Chapter 2

• However, some firms experience very low failure rates of less than 10% while others report very high failure rates in excess of 70%. Chapter 2

• Many biotech tech transfer failures can be traced to an inability on the part of the sponsor to adequately perform initial due diligence. Chapter 3

• Over the next five years, the role of biotechnology in drug development is expected to expand strongly as biotech drug sales rise by 17.7% per year while small molecule drug sales grow by just 2.9% annually. Chapter 4

Key questions answered

• Why is biotech tech transfer rising so quickly? (Because biotechnologies offer a means to address unmet medical needs and many new technologies have been developed outside of Big Pharma)

• Which types of biotech tech transfer approaches are currently most common? (Licensing and acquisitions)

• Which trends will further boost biotech tech transfer in the future? (Economic recovery, healthcare reform, clarification of biosimilars regulation, rising biotech funding)

• What are the most common reasons for the failure of biotech tech transfers? Deficiencies in due diligence, inappropriate deal structure, differing cultures, inappropriate project organization and expectations and technology failure)

Companies mentioned

Eli Lilly , Ensemble Discovery , Gene Network Sciences , Genentech , GlaxoSmithKline , Horizon Discovery , Merck & Co. , Novartis , Novus Biologicals , Thiakis

Table of Contents

Building Biotech Technology Transfer Opportunities

Executive Summary 8

Overview of biotech tech transfer 8

Why biotech tech transfer deals fail 9

Strategies to ensure successful biotech tech transfer deals 10

The future of biotech tech transfer deals 11

Chapter 1 Overview of biotech tech transfer 14

Summary 14

The biotechnology industry today 15

Biotechnology technologies and techniques 15

Proliferation of investigational products 18

Funding issues 18

Need to partner to advance product development 19

The emergence of biotechnology brokers 20

Drug development challenges 21

More complicated disease targets 22

Escalating costs 22

Increased regulatory scrutiny 23

Diminished in-house R&D resources 24

Types of biotech tech transfer relationships 26

Academic R&D infusions 28

Biotech biotech deals 29

Pharma biotech alliances 30

Licensing 32

R&D collaborations 33

Sales, distribution and co-marketing agreements 33

Joint ventures 33

Acquisitions 34

Volume of recent deals 35

Relationship trends 51

Volume and value 51

Ownership 52

Conclusion 53

Chapter 2 Why biotech tech transfer deals fail 56

Summary 56

High failure rates 57

Symptoms of deal failure 57

Factors that do not affect deal failure 58

Implications of deal failure 59

Impact on technology developers 60

Impact on technology sponsors 61

Lost value of failed deals 61

Main causes of biotech tech transfer failure 62

Due diligence failures 64

Technology performance 66

Patent issues 67

Developer organization strength 67

Deal structure 69

Financial compensation 70

Management changes 71

Cultural differences 72

Project organization and expectations 74

Other preventable problems 76

Technology failure 77

Conclusion 77

Chapter 3 Strategies to ensure successful biotech tech transfer deals 80

Summary 80

Measures of success 81

Success for the technology developer 81

Success for the technology sponsor 82

Key biotech tech transfer strategies 82

Strategies for both technology developers and sponsors 82

Meeting technology challenges 82

Strategies for technology developers 85

Optimizing resources 85

Thinking like a customer 88

Working with professional tech transfer organizations 89

Prolific publishing 91

Strategies for technology sponsors 92

Thorough technology identification and due diligence 93

Structuring innovative deal terms 98

Addressing compensation issues 105

Fostering an entrepreneurial developer environment 105

Ensuring effective alliance management 106

Navigating cultural chasms 108

Addressing international intellectual property challenges 110

Conclusion 113

Chapter 4 The future of biotech tech transfer deals 116

Summary 116

Introduction 117

The future of drug development 117

Impact of the economy 119

US healthcare reform 120

Biosimilars 121

Biotechnology in 2010 - 2015 123

Where biotech fits into Big Pharma 125

Dedicated biotechnology companies 127

Biotech tech transfer deal trends 2010 - 2015 129

Volume and value 130

Ownership 132

Intellectual property issues 133

Success rates 134

Conclusion 135

Index 136

List of Figures

Figure 1.1: Frequency of biotech tech transfer deals by type of institution 27

Figure 1.2: Number and volume of biopartnering deals, 1997 - 2009 52

Figure 1.3: Acquisitions as a proportion of biotech tech transfer deals, 53

Figure 2.4: Characteristics of biotech tech transfer failure causes 63

Figure 2.5: Relative importance to sponsor of technology developer 66

Figure 3.6: Strategies to optimize biotech tech transfer opportunities 83

Figure 4.7: Biopharmaceutical vs. other pharmaceutical sales, 2009 - 2015 124

Figure 4.8: Impact of industry and economic trends on conventional and biotech drug developers, 2009 - 2015 125

Figure 4.9: Relative importance of biotechnology for leading pharmaceutical companies, 2009 vs. 2015 127

Figure 4.10: Number and average size of global biotech companies, 2009 - 2015 130

Figure 4.11: Number and volume of biopartnering deals, 2009 - 2015 132

List of Tables

Table 1.1: Definition of biotechnology techniques 17

Table 1.2: Biotech tech transfer deals, 2009 36

Table 1.3: Biotech tech transfer deals, 2009 (Contd.) 37

Table 1.4: Biotech tech transfer deals, 2009 (Contd.) 38

Table 1.5: Biotech tech transfer deals, 2009 (Contd.) 39

Table 1.6: Biotech tech transfer deals, 2009 (Contd.) 40

Table 1.7: Biotech tech transfer deals, 2009 (Contd.) 41

Table 1.8: Biotech tech transfer deals, 2009 (Contd.) 42

Table 1.9: Biotech tech transfer deals, 2009 (Contd.) 43

Table 1.10: Biotech tech transfer deals, 2009 (Contd.) 44

Table 1.11: Biotech tech transfer deals, 2009 (Contd.) 45

Table 1.12: Biotech tech transfer deals, 2009 (Contd.) 46

Table 1.13: Biotech tech transfer deals, 2009 (Contd.) 47

Table 1.14: Biotech tech transfer deals, 2009 (Contd.) 48

Table 1.15: Biotech tech transfer deals, 2009 (Contd.) 49

Table 1.16: Biotech tech transfer deals, 2009 (Contd.) 50

Table 3.17: Technology transfer areas of interest for Merck & Co., 2010 95

Table 3.18: Technology transfer areas of interest for Merck & Co., 2010 (Contd.) 96

Table 3.19: Novartis private equity fund holdings, 2010 100

Table 3.20: Novartis private equity fund holdings, 2010 (Contd.) 101

Table 3.21: Novartis private equity fund holdings, 2010 (Contd.) 102

Table 3.22: Novartis private equity fund holdings, 2010 (Contd.) 103

Table 4.23: Millions of older and overweight persons in the US and EU, 2009 - 2015 119

Table 4.24: Biosimilars approved in the US and EU, 2010 121

To order this report:

Biotechnology Industry: Building Biotech Technology Transfer Opportunities: Sponsor and developer strategies for success

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
2. Photo-catalytic, self cleaning coating for building exteriors
3. Techstreet Launches BuildingBlocks Utility for Industry Standards Saving Time and Increasing Productivity for Engineers
4. Arts Way Manufacturing Announces Launch of New Web Site For Arts Way Scientific - Buildings For Science
5. Secret of sandcastle construction could help revive ancient building technique, researchers say
6. Building better bone replacements with bacteria
7. Hendrick Construction Renovates USC Science Building
8. RPJ Housings Rebuilding Together Event Brings Estimated $300,000 Worth Of Volunteer Labor to Northern VA
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Yongye Biotechnology International Retains CCG Investor Relations
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):